LYMPHOSEEK KIT Drug Patent Profile
✉ Email this page to a colleague
When do Lymphoseek Kit patents expire, and when can generic versions of Lymphoseek Kit launch?
Lymphoseek Kit is a drug marketed by Cardinal Health 414 and is included in one NDA. There are two patents protecting this drug.
This drug has thirty patent family members in twelve countries.
The generic ingredient in LYMPHOSEEK KIT is technetium tc-99m tilmanocept. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the technetium tc-99m tilmanocept profile page.
DrugPatentWatch® Generic Entry Outlook for Lymphoseek Kit
Lymphoseek Kit was eligible for patent challenges on March 13, 2017.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be September 27, 2033. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for LYMPHOSEEK KIT
International Patents: | 30 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 24 |
DailyMed Link: | LYMPHOSEEK KIT at DailyMed |

DrugPatentWatch® Estimated Generic Entry Opportunity Date for LYMPHOSEEK KIT
Generic Entry Date for LYMPHOSEEK KIT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
INJECTABLE;INJECTION |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for LYMPHOSEEK KIT
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
John O. Prior | Early Phase 1 |
Stanford University | Phase 2 |
Anna Cruceta | Phase 4 |
US Patents and Regulatory Information for LYMPHOSEEK KIT
LYMPHOSEEK KIT is protected by two US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of LYMPHOSEEK KIT is See Plans and Pricing.
This potential generic entry date is based on patent See Plans and Pricing.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting LYMPHOSEEK KIT
Macromolecular carrier for drug and diagnostic agent delivery
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Compositions for radiolabeling diethylenetriaminepentaacetic acid (DTPA)-dextran
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
FDA Regulatory Exclusivity protecting LYMPHOSEEK KIT
NEW PATIENT POPULATION
Exclusivity Expiration: See Plans and Pricing
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cardinal Health 414 | LYMPHOSEEK KIT | technetium tc-99m tilmanocept | INJECTABLE;INJECTION | 202207-001 | Mar 13, 2013 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
Cardinal Health 414 | LYMPHOSEEK KIT | technetium tc-99m tilmanocept | INJECTABLE;INJECTION | 202207-001 | Mar 13, 2013 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
Cardinal Health 414 | LYMPHOSEEK KIT | technetium tc-99m tilmanocept | INJECTABLE;INJECTION | 202207-001 | Mar 13, 2013 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for LYMPHOSEEK KIT
When does loss-of-exclusivity occur for LYMPHOSEEK KIT?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 10208624
Estimated Expiration: See Plans and Pricing
Brazil
Patent: 1007487
Estimated Expiration: See Plans and Pricing
Canada
Patent: 50230
Estimated Expiration: See Plans and Pricing
China
Patent: 2301429
Estimated Expiration: See Plans and Pricing
European Patent Office
Patent: 92012
Estimated Expiration: See Plans and Pricing
Patent: 84965
Estimated Expiration: See Plans and Pricing
Japan
Patent: 43905
Estimated Expiration: See Plans and Pricing
Patent: 40276
Estimated Expiration: See Plans and Pricing
Patent: 09796
Estimated Expiration: See Plans and Pricing
Patent: 33892
Estimated Expiration: See Plans and Pricing
Patent: 12516328
Estimated Expiration: See Plans and Pricing
Patent: 15164933
Estimated Expiration: See Plans and Pricing
Patent: 17066148
Estimated Expiration: See Plans and Pricing
Patent: 19178133
Estimated Expiration: See Plans and Pricing
Patent: 21088566
Estimated Expiration: See Plans and Pricing
South Korea
Patent: 1713559
Estimated Expiration: See Plans and Pricing
Patent: 1765717
Estimated Expiration: See Plans and Pricing
Patent: 110115148
Estimated Expiration: See Plans and Pricing
Patent: 170027874
Estimated Expiration: See Plans and Pricing
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering LYMPHOSEEK KIT around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 2017066148 | ジエチレントリアミン五酢酸(DTPA)−デキストランを放射標識するための組成物 (COMPOSITION FOR RADIOLABELING DIETHYLENETRIAMINEPENTAACETIC ACID (DTPA)-DEXTRAN) | See Plans and Pricing |
Canada | 2750230 | COMPOSITIONS DE RADIOMARQUAGE D'ACIDE DIETHYLENETRIAMINEPENTAACETIQUE (DTPA)-DEXTRAN (COMPOSITIONS FOR RADIOLABELING DIETHYLENETRIAMINEPENTAACETIC ACID (DTPA)-DEXTRAN) | See Plans and Pricing |
Japan | 2015164933 | ジエチレントリアミン五酢酸(DTPA)−デキストランを放射標識するための組成物 (COMPOSITIONS FOR RADIOLABELING DIETHYLENETRIAMINEPENTAACETIC ACID (DTPA)-DEXTRAN) | See Plans and Pricing |
European Patent Office | 2392012 | COMPOSITIONS DE RADIOMARQUAGE D'ACIDE DIÉTHYLÈNETRIAMINEPENTAACÉTIQUE (DTPA)-DEXTRAN (COMPOSITIONS FOR RADIOLABELING DIETHYLENETRIAMINEPENTAACETIC ACID (DTPA)-DEXTRAN) | See Plans and Pricing |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for LYMPHOSEEK KIT
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1178838 | 122015000033 | Germany | See Plans and Pricing | PRODUCT NAME: TILMANOCEPT; REGISTRATION NO/DATE: C(2014) 8901 FINAL 20141119 |
1178838 | 1590025-1 | Sweden | See Plans and Pricing | PRODUCT NAME: TILMANOCEPT; REG. NO/DATE: EU/1/14/955 20141120 |
1178838 | 300736 | Netherlands | See Plans and Pricing | PRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119 |
1178838 | 15C0033 | France | See Plans and Pricing | PRODUCT NAME: TILMANOCEPT; REGISTRATION NO/DATE: EU/1/14/955 20141121 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |